<DOC>
	<DOC>NCT02956967</DOC>
	<brief_summary>Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia</brief_summary>
	<brief_title>Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<criteria>Male and female patients ≥ 18 years Declaration of informed consent signed by patient Patients with a solid tumour or with a malignant haematological tumour Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle GCSFnaïve patients or patients pretreated with GCSF who received no GCSF in the last three months before enrolment Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapyinduced FN Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS) Patients who are hypersensitive to one of the excipients of NivestimTM Patients not undergoing chemotherapy Patients being treated curatively or as secondary prophylaxis with GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Interventional Study</keyword>
</DOC>